Conduit Pharmaceuticals
About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
24% more funds holding
Funds holding: 29 [Q2] → 36 (+7) [Q3]
0.18% more ownership
Funds ownership: 4.04% [Q2] → 4.22% (+0.18%) [Q3]
85% less capital invested
Capital invested by funds: $3.18M [Q2] → $480K (-$2.7M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for CDT.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio.
Neutral
GlobeNewsWire
4 weeks ago
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
SAN DIEGO and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.
Positive
InvestorPlace
4 months ago
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.
Neutral
GlobeNewsWire
4 months ago
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656 AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the selection of initial indications for its lead clinical candidate, HK-4 glucokinase activator AZD1656 licensed from AstraZeneca on August 7, 2024. Conduit intends to initiate Phase 2a clinical trials to evaluate AZD1656 for the treatment of systemic lupus erythematosus (including lupus nephritis) and ANCA-associated vasculitis.
Positive
24/7 Wall Street
4 months ago
4 Stocks Moving Sharply Before the Market Opens
Premarket trading is some of my favorite trading to watch.
Positive
InvestorPlace
4 months ago
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced an exclusive license agreement with AstraZeneca (NASDAQ: AZN ). This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca.
Neutral
GlobeNewsWire
4 months ago
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertility Assets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”), today announced that the Company has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO).
Charts implemented using Lightweight Charts™